Alpha lactalbumin

Alpha-Lactalbumin: A Comprehensive Reference

1. Identity

Chemical and Systematic Names

Alpha-lactalbumin, also known as α-lactalbumin and LALBA, is a protein that in humans is encoded by the LALBA gene. α-Lactalbumin (α-LA) is a small (molecular weight approximately 14,200 Da), acidic (pI 4–5), calcium-binding protein. The molecular weight is 14,178 Da, and the isoelectric point is between 4.2 and 4.5.

Natural Sources

α-Lactalbumin is a protein that regulates the production of lactose in the milk of almost all mammalian species. It is present in the milk of humans, cows, goats, and other mammals. Alpha-lactalbumin comprises 20–25% of total human breast milk protein and is the primary protein found in human breast milk. In bovine (cow's) whey, its proportion differs: β-lactoglobulin constitutes the largest fraction of whey protein at 55–60 wt.%, followed by α-lactalbumin at 15–25 wt.%. The milk of all mammals that contain lactose also contains α-lactalbumin.

Common Forms and Preparations

Alpha-lactalbumin is commercially isolated from bovine whey through various fractionation processes. Commercial production methods typically start with whey protein mixtures generated from dairy sources such as raw milk, skim milk, and partially defatted milk, obtained either through microfiltration of milk (native whey) or the separation of whey from curds during cheesemaking (cheese whey). The resulting α-lactalbumin-enriched compositions may be further enriched by treating with protease enzymes that selectively hydrolyze residual β-lactoglobulin aggregates while leaving α-LA mostly unhydrolyzed; the larger α-LA proteins are then separated in a second membrane filtration, and the final α-LA-enriched composition is commonly dried into a powder.

Available preparations include:

• Enriched whey protein powders: Blends in which α-lactalbumin represents a higher-than-standard fraction of total whey protein, used in sports and adult nutrition products.
• High-purity isolated α-lactalbumin powders: Used in research and specialized clinical infant formulas.
• α-Lactalbumin-enriched infant formulas: Considered ideal for lower-protein infant formulas due to its high content of essential amino acids, particularly tryptophan.
• Partially hydrolyzed (peptide) forms: Partially hydrolyzed α-LA can form nanotubes. Hydrolysates are also used in hypoallergenic formula research.

Structural Overview

The structure of alpha-lactalbumin is comprised of 123 amino acids and 4 disulfide bridges, and the protein has a molecular weight of 14.2 kDa. All α-LAs contain 8 cysteines, which form four disulfide bonds crucial for the formation of the native fold of these proteins. Alpha-lactalbumin has two prominent forms: the holo-state, which is the natural form — folded and bound by calcium — and the apo-state, which occurs in acidic conditions and is associated with the release of calcium ions and β-sheet unfolding.

α-LA has a single strong calcium-binding site, which is formed by oxygen ligands from carboxylic groups of three Asp residues (82, 87, and 88) and from two carbonyl groups of the peptide backbone (Lys79 and Asp84) in a loop between two helices. Usually, a part of α-LA is glycosylated in fresh milk.

2. History and Discovery

Evolutionary Origins

The lysozyme C gene gave rise, after gene duplication 300 to 400 million years ago, to a gene that currently codes for alpha-lactalbumin, a protein expressed only in the lactating mammary gland of all but a few species of mammals. It is required for the synthesis of lactose. Alpha-lactalbumin shares only 40% identity in amino acid sequence with lysozyme C but has a closer spatial structure and gene organization. Although structurally similar, functionally they are quite distinct.

The common ancestry of the genes for α-lactalbumin, which is found only in mammals, and lysozymes, which are ubiquitous in eukaryotes, suggests that the α-lactalbumins developed through duplication of an ancestral lysozyme gene followed by mutational divergence that led to the development of a new protein function. Specific amino acid substitutions in α-LA resulted in the loss of the lysozyme catalytic activity and created the features necessary for the role of α-LA in lactose synthesis.

Scientific History

Because of its relative abundance and ease of purification, α-lactalbumin served as a model for the early development of methods for investigating the chemical and biophysical properties of proteins. Although initially it had been considered to have only nutritional significance, in 1967–68 it was discovered that α-lactalbumin has a key function in the biosynthesis of lactose and the production of the aqueous phase of milk. Contemporaneous structural studies also revealed that bovine α-lactalbumin is similar in amino acid sequence and disulfide bond arrangements to type-c lysozymes from birds and mammals.

A pivotal advancement came in 1955 when Aschaffenburg and Drewry developed an improved crystallization method for α-lactalbumin from bovine milk, formally distinguishing it as a specific isoform within the lactalbumin family and enabling purer preparations for study. The 1960s marked the recognition of α-lactalbumin's functional role, with Brew et al. (1968) identifying it as the essential regulator of galactosyltransferase in lactose biosynthesis, transforming its understanding from a mere structural component to a key enzymatic modifier. In the 1970s, Brew et al. (1971) determined the complete 123-amino-acid sequence of bovine α-lactalbumin, uncovering about 40% identity with lysozyme and hinting at a shared evolutionary origin through a lysozyme-like fold.

α-Lactalbumin was the subject of an early exercise in homology-based modeling, which showed that its amino acid sequence is consistent with a close similarity in three-dimensional structure to lysozyme; this early model was surprisingly correct, but was not confirmed until the first three-dimensional structure of an α-lactalbumin was determined in 1989.

Traditional and Historical Use

Alpha-lactalbumin does not have a documented history of intentional traditional medicinal use as an isolated substance in any known ethnobotanical or traditional medicine system. Its "traditional" context is entirely dietary: as a constituent of mammalian milk, it has been consumed by humans across all cultures in which milk feeding (of human infants) or dairying was practiced. Bovine milk — and therefore bovine α-lactalbumin — has been consumed by human populations in dairying cultures for approximately 10,000 years, primarily as a food rather than as a targeted therapeutic agent.

The recognition of alpha-lactalbumin as a distinct, characterizable protein with its own specific biological properties is entirely a product of twentieth-century biochemistry. Its clinical and nutritional application as an isolate or enriched fraction is a modern (post-1990) development, driven by its characterization in the laboratory rather than by traditional use. No traditional medicinal monographs (WHO, ESCOP, Commission E, or pharmacopeial) exist for alpha-lactalbumin as an isolated ingredient.

3. Key Constituents and Active Compounds

Amino Acid Profile

Alpha-lactalbumin is particularly rich in lysine, cysteine, and the branched-chain amino acids leucine, isoleucine, and valine, while also containing a comparatively high concentration of tryptophan. The tryptophan content of α-lactalbumin is nearly double that of standard whey protein, at approximately 48 mg per gram compared with 27 mg per gram.

This amino acid profile positions α-lactalbumin at the intersection of muscle metabolism and neurochemical regulation. Tryptophan-rich α-lactalbumin is abundant in human milk but limited in bovine milk.

Calcium-Binding Function

α-Lactalbumin is a Ca²⁺ binding protein with a single strong calcium-binding site. As a multimer, α-lactalbumin strongly binds calcium and zinc ions. Calcium binding is critical to maintaining the protein's native tertiary structure. In the absence of calcium (apo-state), the protein adopts a partially unfolded, "molten globule" conformation that is central to several of its emerging bioactivities.

Regulatory Role in Lactose Synthesis

α-Lactalbumin forms the regulatory subunit of the lactose synthase (LS) heterodimer, and β-1,4-galactosyltransferase (beta4Gal-T1) forms the catalytic component. Together, these proteins enable lactose synthase to produce lactose by transferring galactose moieties to glucose. Beta-1,4-galactosyltransferase can transfer UDP galactose to glucose, but the Km for glucose is 1,400 mM, making the reaction too slow to be physiologically meaningful. Alpha-lactalbumin serves to lower the Km for glucose to 5 mM, enabling the enzyme complex to add UDP-galactose to glucose to produce lactose efficiently.

Bioactive Peptides and Complexes

α-LA and some of its fragments possess bactericidal and antiviral activities. Complexes of partially unfolded α-LA with oleic acid showed significant cytotoxicity to various tumor and bacterial cells. In such complexes, α-LA plays a role of a delivery carrier of cytotoxic fatty acid molecules into tumor cells across the cell membrane.

In addition to its role as a source of essential amino acids, α-lactalbumin is believed to offer several potential health benefits, including antimicrobial properties, enhancement of immune function, and absorption of zinc and calcium.

4. Mechanisms of Action

Tryptophan Transport and Serotonin Synthesis

Brain uptake of the serotonin precursor tryptophan is dependent on nutrients that influence the availability of tryptophan via a change in the ratio of plasma tryptophan to the sum of the other large neutral amino acids (Trp:LNAA). Because alpha-lactalbumin has a high tryptophan content and a relatively lower proportion of competing large neutral amino acids (LNAAs), its ingestion raises the plasma Trp:LNAA ratio more effectively than most other protein sources. The uptake of the serotonin precursor tryptophan into the brain is dependent on nutrients that influence the cerebral availability of tryptophan via a change in the ratio of plasma tryptophan to the sum of the other large neutral amino acids (Trp:LNAA ratio). A diet-induced increase in tryptophan availability may increase brain serotonin synthesis and improve coping and mood, particularly in stress-vulnerable subjects.

Enrichment of α-lactalbumin in formula led to higher circulating tryptophan and increased serotonin levels in the striatum. α-Lactalbumin (α-LA), a key component of whey protein that is rich in tryptophan, has been shown to promote the synthesis of serotonin and melatonin, thereby regulating sleep cycles.

HAMLET Complex: Cytotoxic Mechanism

HAMLET (human alpha-lactalbumin made lethal to tumor cells) is a molecular complex derived from human milk that kills tumor cells by a process resembling programmed cell death. The complex consists of partially unfolded alpha-lactalbumin and oleic acid, and both the protein and the fatty acid are required for cell death.

Because native alpha-lactalbumin itself cannot trigger cell death, HAMLET's remarkable tumor-selective cytotoxicity has been strongly correlated with the conformational change of the protein upon forming the complex. Research concludes that the protein portion of HAMLET and other HAMLET-like protein-oleic acid complexes is not the origin of their cytotoxicity to tumor cells; rather, the protein portion plays a role in the delivery of cytotoxic oleic acid molecules into tumor cells across the cell membrane.

The complex of human α-lactalbumin with oleic acid with the antitumor activity of HAMLET was found to be naturally present in the acidic fraction of human breast milk. Since the discovery of HAMLET in the 1990s, a wealth of information has been accumulated, illuminating the structural, functional and therapeutic properties of protein complexes with oleic acid.

Calcium and Zinc Mineral Binding

The calcium-binding properties of α-lactalbumin may contribute to its role as a mineral carrier in milk, potentially influencing the intestinal absorption of calcium and zinc. This mechanism is proposed but has not been definitively characterized in high-quality human studies. As a multimer, α-lactalbumin strongly binds calcium and zinc ions.

5. Scientific Evidence by Area of Use

5.1 Infant Nutrition and Growth

This is the most extensively studied clinical application of alpha-lactalbumin. The primary rationale is to reduce total protein in infant formula while maintaining adequate essential amino acid supply, thereby more closely approximating the composition of human breast milk.

A multicenter study aimed to evaluate the efficacy and safety of an α-lactalbumin-enriched formula with a protein profile and total protein concentration closer to human milk. Two hundred and sixteen healthy term infants ≤14 days of postnatal age were enrolled, and 166 (76.9%) completed the study. Timed post-prandial plasma essential amino acid levels were determined after 8 weeks of ad libitum feeding. At 8 weeks, all mean plasma essential amino acid levels in the experimental formula group were as high as in the standard formula and human milk groups. The incidence of feeding-related gastrointestinal events varied significantly (P = 0.025) across groups: standard formula (31.3%), experimental formula (17.2%), and human milk (13.6%), with standard formula being significantly higher than human milk.

A prospective randomized, double-blind, controlled trial demonstrated that an α-lactalbumin–enriched infant formula with a protein content of 1.89 g protein/100 kcal is suitable and safe for the exclusive nutrition of infants in the first months of life and supports adequate growth. This was a randomized, double-blind controlled trial with 80 healthy newborn infants assigned to receive either an isocaloric low- or high-protein content formula (1.89 versus 2.1 g/100 kcal); the low-protein content formula was enriched with α-lactalbumin, and a breast-fed reference group of 40 infants was studied concurrently.

A randomized clinical trial demonstrated that the lower protein α-lactalbumin-enriched formula is appropriate for term infants as evidenced by age-appropriate growth, markers of protein status, plasma essential amino acid concentrations, and gastrointestinal tolerance. Infants randomized to the lower protein formula had growth outcomes similar to human milk-fed infants in terms of weight gain, weight-for-age Z-score, and weight-for-length Z-score.

Clinical trials have confirmed that formulas enriched with α-lactalbumin are safe, support adequate growth, increase energetic efficiency, and improve gastrointestinal tolerance in infants.

Evidence strength: Moderate-to-strong for infant formula applications. Multiple randomized controlled trials with controlled comparator groups support safety and adequacy of growth when α-lactalbumin-enriched, lower-protein formulas are used. The evidence is strongest for growth outcomes and gastrointestinal tolerability, and less definitive regarding longer-term metabolic and developmental outcomes.

5.2 Sleep Quality

This is an active and growing area of clinical investigation in both healthy adults and athletic populations.

Behavioral (reaction time and errors) and brain measures of attention were recorded during a continuous performance task in a crossover sleep laboratory study. Evening alpha-lactalbumin intake caused a 130% increase in Trp:LNAA before bedtime (P = 0.0001) and modestly but significantly reduced sleepiness (P = 0.013) and improved brain-sustained attention processes (P = 0.002) the following morning. Only in poor sleepers was this accompanied by improved behavioral performance (P = 0.05). Evening dietary increases in plasma tryptophan availability enhance sustained alertness early in the morning after overnight sleep, most likely because of improved sleep.

A 2024 systematic review published in the Journal of Sleep Research comprehensively evaluated this literature: Four electronic databases were searched from inception to March 2023; eight studies were reviewed, with four recruiting athletic populations and four recruiting healthy participants. Sleep or sleepiness was measured objectively in six studies, with two studies employing polysomnography and four utilizing actigraphy. Across the studies, 20–60 g of α-lactalbumin was supplemented, with five studies (63%) observing a positive association between α-lactalbumin and sleep.

Data from this review suggest that individuals that have difficulty initiating sleep may benefit most from pre-sleep α-lactalbumin supplementation. Further research is required to establish the effect that α-lactalbumin has on sleep architecture, through the use of more comprehensive sleep analysis tools such as portable electroencephalography or polysomnography, in combination with stringent dietary controls.

Despite these clear biochemical effects, clinical outcomes related to sleep have been variable. Evening consumption of a whey protein rich in the amino acid tryptophan, alpha-lactalbumin (ALAC), has previously been shown to benefit sleep — particularly among poor sleepers.

Evidence strength: Preliminary to moderate. Eight studies have been reviewed, and the majority report positive associations, particularly for sleep-onset latency in those with difficulty falling asleep. However, individual studies vary substantially in design, population, dose, and outcome measurement. The biochemical mechanism (Trp:LNAA elevation) is robustly demonstrated; downstream effects on objective sleep architecture (e.g., polysomnography) require further confirmatory study.

5.3 Mood, Stress, and Cognitive Function

The bovine protein α-lactalbumin increases the plasma ratio of tryptophan to the other large neutral amino acids, and in vulnerable subjects raises brain serotonin activity, reduces cortisol concentration, and improves mood under stress. This was established in a landmark double-blind, placebo-controlled crossover study published in the American Journal of Clinical Nutrition in 2000, by Markus et al., which specifically found effects in participants with high neuroticism scores ("stress-vulnerable" individuals) but not in those who were stress-resilient.

A follow-up study by the same group (Markus et al., 2002) found that whey protein rich in α-lactalbumin increases the ratio of plasma tryptophan to the sum of the other large neutral amino acids and improves cognitive performance in stress-vulnerable subjects.

Markus et al. (2000), using the same laboratory stressor, found a protective effect of α-lactalbumin on stress-induced changes in mood and cortisol in students with high neuroticism scores. However, subsequent research in recovered-depressed subjects has produced more mixed results.

Because tryptophan is an essential amino acid, modifying its availability through dietary intake can directly influence central serotonin metabolism and consequently affective and cognitive processes. A registered clinical trial tested the hypothesis that an acute intake of whey protein with high levels of tryptophan such as alpha-lactalbumin can stabilize the metabolism of serotonin and subsequently enhance metabolic and cognitive functions in healthy older adults.

Evidence strength: Moderate for biochemical endpoints (plasma Trp:LNAA elevation), preliminary for mood and cognitive outcomes. The most consistent finding is that effects are restricted to stress-vulnerable individuals. Effects in healthy, non-vulnerable populations are less reliable. The body of research is relatively small, and studies vary in population and methodology.

5.4 Exercise Recovery and Muscle Metabolism

A crossover counterbalanced study compared the effect of alpha-lactalbumin and whey protein isolate on muscle damage, muscle pain, and mood states during short-term recovery following strenuous prolonged exercise. Twelve endurance male runners ran for 90 minutes at 70% VO₂max, followed by a 4-hour recovery. Two treatments (carbohydrate + alpha-lactalbumin; carbohydrate + whey protein isolate) were applied, with protein administered at 0.34 g/kg/h every 30 minutes. Creatine kinase (CK), interleukin-6 (IL-6), salivary cortisol, rating of muscle pain, pressure pain threshold (PPT), and mood states were evaluated before, immediately after, 2 hours after, and 4 hours after exercise.

A neuromuscular study examined strength and fatigue: The consumption of tryptophan-rich supplements such as α-lactalbumin is of interest because tryptophan is the only precursor for brain serotonin synthesis. A randomised double-blind cross-over study was conducted in which 16 healthy participants performed plantar flexor and handgrip maximal voluntary contractions, a 30-second submaximal handgrip contraction, and a plantar flexor fatigue protocol before and 90 minutes after consuming either 40 g of α-lactalbumin, an isonitrogenous beverage (Zein), or an isocaloric beverage (corn starch).

Evidence strength: Preliminary. Studies in exercise contexts are small in number and sample size. Alpha-lactalbumin's branched-chain amino acid and leucine content support theoretical utility for muscle protein synthesis, and the elevated tryptophan content introduces a serotonin-mediated dimension to fatigue and mood during recovery. Direct comparative superiority over standard whey protein for muscle outcomes remains unproven in well-powered randomized trials.

5.5 Antitumor Activity (HAMLET) — Preclinical and Early Clinical

HAMLET has broad antitumor activity in vitro, and its therapeutic effect has been confirmed in vivo in a human glioblastoma rat xenograft model, in patients with skin papillomas, and in patients with bladder cancer.

HAMLET is a complex of human α-lactalbumin with oleic acid that kills various tumor cells and strains of Streptococcus pneumoniae. More potent protein-OA complexes have also been reported for bovine α-lactalbumin and β-lactoglobulin.

HAMLET (human alpha-lactalbumin made lethal to tumor cells) is a tumoricidal complex consisting of partially unfolded protein and fatty acid and was first identified in casein fractions of human breast milk. The complex can be produced from its pure components through a modified chromatographic procedure where preapplied oleic acid binds with partially unfolded alpha-lactalbumin on the stationary phase in situ. Because native alpha-lactalbumin itself cannot trigger cell death, HAMLET's remarkable tumor-selective cytotoxicity has been strongly correlated with the conformational change of the protein upon forming the complex.

α-LA in the cytotoxic complexes plays a role of a delivery carrier of cytotoxic fatty acid molecules into tumor and bacterial cells across the cell membrane. Perhaps in the future the complexes of α-LA with oleic acid will be used for development of new anti-cancer drugs.

Evidence strength: Predominantly preclinical (cell culture and animal models). Very limited human data exist (skin papillomas, intravesical bladder cancer instillation in small studies). HAMLET is not an approved therapeutic agent and is not available as a dietary supplement. Oral ingestion of alpha-lactalbumin as a supplement does not produce HAMLET, as HAMLET requires specific in vitro preparation conditions (partial unfolding in the presence of oleic acid under controlled chromatographic conditions).

5.6 Antimicrobial Effects

The human milk protein-lipid complex HAMLET disrupts glycolysis and induces death in Streptococcus pneumoniae. α-LA and some of its fragments possess bactericidal and antiviral activities. These effects have primarily been demonstrated in laboratory (in vitro) settings. The degree to which oral supplementation with intact α-lactalbumin translates to clinically meaningful antimicrobial activity in humans remains to be established.

Evidence strength: Preliminary, largely in vitro. No high-quality human clinical trials have tested alpha-lactalbumin supplementation as an antimicrobial intervention.

5.7 Infant Brain Development and Neurodevelopment

Adequate dietary tryptophan is essential for infant cognitive and brain development, as it serves as a precursor for serotonin biosynthesis within the brain. A feeding study with neonatal piglets used an α-lactalbumin-enriched formula and comprehensively monitored tryptophan utilization across serum, urine, liver, and brain using GC-MS and NMR-based metabolomics. Enrichment of α-lactalbumin led to higher circulating tryptophan and increased serotonin levels in the striatum. While these results enhance understanding of the metabolic effects of α-lactalbumin, the influence of these biochemical changes on behavioral and cognitive outcomes remains to be elucidated, and a future clinical study is essential to fully decipher these functional implications.

Evidence strength: Primarily animal model data. Human clinical research in infants has focused on growth and gastrointestinal outcomes; direct neurodevelopmental endpoints have not yet been rigorously tested in controlled human trials.

6. Body Systems Associated With Alpha-Lactalbumin

• Central Nervous System: Via tryptophan → serotonin → melatonin pathway; effects on mood, stress resilience, sleep regulation, and cognitive performance.
• Gastrointestinal System: Improved tolerability in infants compared to standard formula; potential prebiotic and antimicrobial peptide effects.
• Musculoskeletal System: Provision of branched-chain amino acids (leucine, isoleucine, valine) for muscle protein synthesis; proposed role in exercise recovery.
• Endocrine/Neuroendocrine System: Reductions in cortisol observed in stress-vulnerable subjects; downstream effects on melatonin production through serotonin pathway.
• Immune System: As a multimer, α-lactalbumin strongly binds calcium and zinc ions and may possess bactericidal or antitumor activity. Cysteine residues contribute to glutathione precursor availability.
• Mammary Gland / Lactation Biology: Fundamental physiological role as co-enzyme in lactose synthesis in the lactating breast.

7. Dosage Forms and Dosages Reported in Studies

The following dosages reflect what has been reported in published research; they are presented descriptively and not as recommendations.

• Sleep and cognitive studies (adults): Across eight studies reviewed in a 2024 systematic review, 20–60 g of α-lactalbumin was supplemented. One key study tested evening consumption of α-lactalbumin protein with an enriched tryptophan content of 4.8 g/100 g.
• Stress and mood studies: In one study, a 40-gram dose of alpha-lactalbumin produced a rapid and sustained elevation in plasma tryptophan.
• Neuromuscular study: Participants consumed either 40 g of α-lactalbumin, an isonitrogenous beverage (Zein), or an isocaloric beverage (corn starch).
• Exercise recovery: In one endurance exercise study, protein was administered at 0.34 g/kg/h every 30 minutes during the first 2 hours of recovery.
• Infant formula (clinical trials): Trials tested formulas with a protein content of 1.89 g protein/100 kcal (low-protein, α-lactalbumin-enriched) versus 2.1 g/100 kcal. Additional trials tested formulas containing 1.0 g protein/dL, 1.3 g protein/dL, or 1.5 g protein/dL.

8. Safety Considerations and Interactions

Allergenicity

Alpha-lactalbumin is a milk-derived protein and is therefore a dairy allergen. Beta-lactoglobulin, the major component of whey protein in cows' milk, acts as an allergen which can cause infant allergy. Alpha-lactalbumin, while less frequently cited as the primary allergenic protein in cow's milk allergy compared to β-lactoglobulin and caseins, is nonetheless a milk protein and may trigger reactions in milk-allergic individuals. α-Lactalbumin may be more sensitive to temperature, resulting in exposure of allergic epitopes and increasing the allergic potential under certain heating conditions. Individuals with confirmed cow's milk protein allergy should avoid alpha-lactalbumin preparations.

Dairy allergy was explicitly used as an exclusion criterion in clinical trials of α-lactalbumin supplementation.

General Tolerability

In infant formula trials, the α-lactalbumin-enriched experimental formula showed a significantly lower incidence of feeding-related gastrointestinal events compared to standard formula. Study withdrawals due to feeding-related GI events were also significantly lower in the experimental formula group compared to standard formula. In adult supplement studies, gastrointestinal tolerability has not been a prominent adverse finding, consistent with the general tolerability of whey protein products.

Interaction With Serotonergic Medications

Because alpha-lactalbumin raises plasma tryptophan availability and is proposed to increase central serotonin synthesis, a theoretical interaction exists with medications that affect serotonergic neurotransmission. Antidepressant medication use was used as an exclusion criterion in sleep supplementation clinical trials, consistent with the potential for pharmacodynamic interaction with serotonin-modulating drugs (e.g., SSRIs, MAOIs, SNRIs). This interaction has not been formally studied, and the clinical relevance of the interaction at supplemental doses remains unknown.

Lactose Intolerance

Alpha-lactalbumin isolate or enriched preparations contain negligible lactose when properly processed. However, less purified whey-based preparations may retain lactose and could cause symptoms in lactose-intolerant individuals. This depends on the degree of processing of any specific commercial product.

Population-Specific Considerations

Data from infant formula trials suggest that a modest reduction in the total protein concentration of the formula has an effect on growth in the short term; further studies are needed to determine if trends in weight gain observed in lower-protein formula groups have an impact on weight status in later life. This is relevant to the use of α-lactalbumin-enriched lower-protein formulas as substitutes for standard formulas or human milk.

Heat Processing and Structural Integrity

Research has investigated the effect of heating sterilization on the allergenicity of α-lactalbumin by combining molecular dynamics with experimental techniques for detecting spatial structure and IgE binding capacity. The structure of whey protein isolate was found to be substantially altered at heat sterilization conditions of 95 °C for 5 minutes and 65 °C for 30 minutes. Thermal processing at high temperatures may alter both the functional properties and the allergen profile of alpha-lactalbumin, a consideration relevant to infant formula manufacturers and food processors.

References

• Permyakov EA, Berliner LJ. "α-Lactalbumin, Amazing Calcium-Binding Protein." PMC / MDPI Encyclopedia. 2020.
• α-Lactalbumin. Encyclopedia MDPI. Entry 1840. 2020.
• α-Lactalbumin. Wikipedia. (Reviewed 2026.)
• npj Science of Food: "The role of alpha-lactalbumin in modulating tryptophan metabolism and serotonin synthesis." Nature Publishing Group, 2025.
• PMC: "The role of alpha-lactalbumin in modulating tryptophan metabolism and serotonin synthesis." PMC/NIH, 2025.
• ScienceDirect (AJCN): Markus CR et al. "Evening intake of α-lactalbumin increases plasma tryptophan availability and improves morning alertness and brain measures of attention." 2005.
• PubMed: Markus CR et al. "Evening intake of alpha-lactalbumin increases plasma tryptophan availability and improves morning alertness and brain measures of attention." Am J Clin Nutr. 2005.
• Journal of Sleep Research: Barnard J et al. "Alpha-lactalbumin and sleep: A systematic review." 2024.
• PubMed: Barnard J et al. "Alpha-lactalbumin and sleep: A systematic review." J Sleep Res. 2024.
• PMC: "Effect of an α-lactalbumin-enriched infant formula with lower protein on growth." Eur J Clin Nutr. 2011.
• European Journal of Clinical Nutrition: "Effect of an α-lactalbumin-enriched infant formula with lower protein on growth." 2010.
• ScienceDirect (Nutrition): "Adequacy and safety of α-lactalbumin–enriched low-protein infant formula: A randomized controlled trial." 2020.
• PubMed: "Adequacy and safety of α-lactalbumin-enriched low-protein infant formula: A randomized controlled trial." 2020.
• European Journal of Clinical Nutrition: "α-Lactalbumin-rich infant formula fed to healthy term infants in a multicenter study: plasma essential amino acids and gastrointestinal tolerance." 2007.
• European Journal of Clinical Nutrition: "α-Lactalbumin-enriched and probiotic-supplemented infant formula in infants with colic: growth and gastrointestinal tolerance." 2010.
• PMC: "Lower Protein Intake Supports Normal Growth of Full-Term Infants Fed Formula: A Randomized Controlled Trial." 2018.
• PubMed: Lonnerdal B et al. "Effects of alpha-lactalbumin-enriched formula containing different concentrations of glycomacropeptide on infant nutrition." 2008.
• PubMed: "alpha-Lactalbumin, engineered to be nonnative and inactive, kills tumor cells when in complex with oleic acid." 2009.
• PubMed: Mossberg AK et al. "Structure and function of human α-lactalbumin made lethal to tumor cells (HAMLET)-type complexes." FEBS J. 2010.
• PubMed: "Apoptosis and tumor cell death in response to HAMLET." 2008.
• PubMed: "Molecular mechanisms of the cytotoxicity of human α-lactalbumin made lethal to tumor cells (HAMLET)." 2013.
• PubMed: "Structural characterization of more potent alternatives to HAMLET." 2013.
• British Journal of Nutrition: Merens W et al. "The effects of a diet enriched with α-lactalbumin on mood and cortisol response in unmedicated recovered depressed subjects and controls." 2005.
• Frontiers in Physiology: "Effects of Alpha-Lactalbumin or Whey Protein Isolate on Muscle Damage, Muscle Pain, and Mood States Following Prolonged Strenuous Endurance Exercise." 2017.
• PMC: "Effects of Alpha-Lactalbumin or Whey Protein Isolate on Muscle Damage, Muscle Pain, and Mood States." Frontiers in Physiology. 2017.
• European Journal of Applied Physiology: "Effects of α-lactalbumin on strength, fatigue and psychological parameters: a randomised double-blind cross-over study." 2022.
• ClinicalTrials.gov: "Effects of Alpha-lactalbumin Intake on Metabolic and Cognitive Functions in Elderly." NCT02082418.
• ScienceDirect Topics: Lactalbumin — Overview. Food Science.
• ScienceDirect Topics: Alpha-Lactalbumin — Overview. Agricultural and Biological Sciences.
• PubMed: "Molecular divergence of lysozymes and alpha-lactalbumin." 1997.
• PubMed: Barnard J et al. "Evening Alpha-Lactalbumin Supplementation Alters Sleep Architecture and Reduces Morning Reaction Time in an Athletically Trained Population With Sleep Difficulties." IJSNEM. 2025.
• PMC: "Pre-Sleep Alpha-Lactalbumin Supplementation Does Not Improve the Habitual Sleep and Performance of Sportspeople with Sleep Difficulties." 2025.
• PMC: Li J, Bian X. "Optimizing Sleep in Athletes: The Potential of α-Lactalbumin in Nutrition Intervention." 2025.
• PMC: "Investigation of the Structure and Allergic Potential of Whey Protein by Both Heating Sterilization and Simulation with Molecular Dynamics." 2022.
• RCSB PDB: 1A4V — ALPHA-LACTALBUMIN (X-ray structure, human, 1.8 Å).